Clinical Trial Update: Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) [Phase 3]

View source ↗

Summary

Phase 3 trial update showing safety and efficacy of Zemplar capsules (paricalcitol) in reducing serum iPTH levels in adults with chronic kidney disease when giv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Renal Insufficiency, Chronic | Phase 3 | Status: COMPLETED